ArticleAsian journal of urology2025
Risk analysis of adverse pathological changes in cT2cN0M0 prostate cancer after robot-assisted radical prostatectomy: Results from a population-based study.
Article in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore clinicopathological predictors of adverse pathological changes (APCs) (upgrading, upstaging, and positive surgical margin [PSM]) after robot-assisted radical prostatectomy (RARP) in clinical tumor stage 2c (cT2c) prostate cancer (PCa) patients. Methods: From January 2018 to December 2022, cT2cN0M0 PCa patients who underwent prostate biopsies and subsequent RARP at the Peking University First Hospital with an interval between biopsy and RARP of ≤90 days were included. Univariable and stepwise multivariable logistic regression analyses were performed to identify independent risk factors associated with APCs. Nomograms were constructed based on these predictive models. The performance of the nomograms was evaluated by receiver operating characteristic curves, decision curve analyses, and calibration plots. Results: A total of 423 eligible cT2cN0M0 PCa patients were included. The rates of upgrading, upstaging, and PSM in our cohort were 33%, 51%, and 35%, respectively. The stepwise multivariate logistic analysis suggested that PSA density and the percentage of positive cores in systematic biopsy were significantly associated with the occurrence of APCs. The score of the Prostate Imaging Reporting and Data System, PSA density, and the International Society of Urological Pathology grade group (IGG) of needle-biopsy specimens (or clinical IGG [cIGG]) were significantly associated with upgrading. The PSA density, percentage of positive cores in systematic biopsy, and largest tumor percentage in all cores of each patient (LTP) were significantly associated with upstaging. The PSA density and LTP were significantly associated with the PSM. Based on these results, four nomograms were developed. Receiver operating characteristic curves, decision curve analyses, and calibration plots implied that the nomograms exhibited excellent accuracy. Conclusion: The predictive models we developed could help to identify high-risk PCa early, and optimize clinical decisions of cT2cN0M0 PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.